RESUMO
BACKGROUND: A factor XIII (FXIII) level >30% is considered necessary to prevent spontaneous bleeding. Bleeding is also a risk in patients with acquired FXIII deficiency, but the hemostatic level of FXIII in this context remains to be determined. METHODS: We retrospectively analyzed all patients diagnosed with acquired FXIII deficiency at a large hospital over 3 years (study ID NCT04416594, http://www.clinicaltrials.gov) and assessed clinical data to identify the best cut-off point for FXIII activity to distinguish between low and high risk of major bleeding in a mixed medical and surgical population. RESULTS: Of the 97 patients who experienced bleeding despite a normal coagulation test, 43.2% had FXIII activity <70%. FXIII activity was significantly lower in surgical patients and patients admitted to the intensive care unit (ICU). Low FXIII activity was significantly associated with long ICU stays and a high incidence of major bleeding. CONCLUSION: Acquired FXIII deficiency is associated with high morbidity. The hemostatic level of FXIII in the setting of acquired FXIII deficiency might be above 30%.
Assuntos
Deficiência do Fator XIII/complicações , Morbidade/tendências , Adulto , Idoso , Idoso de 80 Anos ou mais , Deficiência do Fator XIII/epidemiologia , Feminino , Hemostáticos/análise , Hemostáticos/sangue , Hemostáticos/classificação , Humanos , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
We describe seven critically ill and seven noncritically ill patients with coronavirus disease 2019 infection. Two viscoelastic assays were performed with ClotPro technology, activated by extrinsic system test and recombinant tissue plasminogen activator challenge test. Coagulation profile presents a marked hypercoagulability with increased resistance to fibrinolysis, reflected by tissue plasminogen activator test. Our pathological observations show that the hypercoagulative status described in these patients is, at least partially, secondary to fibrinolysis shutdown.
Assuntos
COVID-19/sangue , Fibrinólise , SARS-CoV-2 , Trombofilia/etiologia , Adulto , Idoso , Contagem de Células Sanguíneas , Testes de Coagulação Sanguínea , COVID-19/complicações , Comorbidade , Estado Terminal , Progressão da Doença , Feminino , Hemorragia/epidemiologia , Hemorragia/etiologia , Mortalidade Hospitalar , Hospitais Urbanos , Humanos , Unidades de Terapia Intensiva , Masculino , Pessoa de Meia-Idade , Quartos de Pacientes , Proteínas Recombinantes , Espanha/epidemiologia , Tromboembolia/epidemiologia , Tromboembolia/etiologia , Trombofilia/sangue , Ativador de Plasminogênio TecidualRESUMO
Early descriptions of COVID-19 associated coagulopathy identified it as a disseminated intravascular coagulation (DIC). However, recent studies have highlighted the potential role of endothelial cell injury in its pathogenesis, and other possible underlying mechanisms are being explored. This study aimed to analyse the coagulation parameters of critically and noncritically ill patients with COVID-19 bilateral pneumonia, determine if coagulation factors consumption occurs and explore other potential mechanisms of COVID-19 coagulopathy. Critically and noncritically ill patients with a diagnosis of COVID-19 bilateral pneumonia were recruited. For each patient, we performed basic coagulation tests, quantification of coagulation factors and physiological inhibitor proteins, an evaluation of the fibrinolytic system and determination of von Willebrand Factor (vWF) and ADAMTS13. Laboratory data were compared with clinical data and outcomes. The study involved 62 patients (31 ICU, 31 non-ICU). The coagulation parameters assessment demonstrated normal median prothrombin time (PT), international normalized ratio (INR) and activated partial thromboplastin time (APTT) in our cohort and all coagulation factors were within normal range. PAI-1 median levels were elevated (median 52.6âng/ml; IQR 37.2-85.7), as well as vWF activity (median 216%; IQR 196-439) and antigen (median 174%; IQR 153.5-174.1). A mild reduction of ADAMTS13 was observed in critically ill patients and nonsurvivors. We demonstrated an inverse correlation between ADAMTS13 levels and inflammatory markers, D-dimer and SOFA score in our cohort. Elevated vWF and PAI-1 levels, and a mild reduction of ADAMTS13 in the most severe patients, suggest that COVID-19 coagulopathy is an endotheliopathy that has shared features with thrombotic microangiopathy.